Resources from the same session
Incorporating CDK 4-6 inhibitors in patients with high-risk HR positive/ HER2 negative early breast cancer: Challenging clinical scenarios with the use of PARP inhibitors and immune-checkpoint inhibitors
Presenter: D. Trapani, IT
Session: Session 1 – CDK4-6 inhibitors in early breast cancer
Resources:
Slides
Webcast